Home › Phases › Phase 3

Phase 3 (110 companies)

Companies with at least one active program at Phase 3.

Ticker Company Therapeutic areas Phase 3 programs Lead stage Mkt cap Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare 2 Phase 3 $608M 5
AARD Aardvark Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $25.2M 3
ABVX Abivax Immunology 1 Phase 3 $7.19B 2
ACIU AC Immune Neurology Rare 1 Phase 3 $210M 11
ALDX Aldeyra Therapeutics DermatologyOncology+1 2 NDA Submitted $41.9M 5
ALT Altimmune GI/HepatologyMetabolic+1 1 Phase 3 $298M 3
ALMS Alumis DermatologyImmunology+1 1 Phase 3 $628M 5
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.54B 5
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 2 Approved $1.36B 9
ANNX Annexon HematologyNeurology+2 Rare 2 Phase 3 $662M 6
RCUS Arcus Biosciences DermatologyImmunology+1 3 Phase 3 $2.36B 8
ARDX Ardelyx GI/HepatologyRenal 1 Approved $799M 4
AVBP ArriVent BioPharma Oncology 1 Phase 3 $553M 7
AXSM Axsome Therapeutics Neurology Rare 6 Approved $7.15B 15
BLTE Belite Bio MetabolicOphthalmology Rare 1 NDA Submitted $6.35B 6
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 1 Approved $1.93B 4
BCTX BriaCell Therapeutics Oncology 1 Phase 3 $30.7M 8
CADL Candel Therapeutics Oncology 2 Phase 3 $424M 4
CRDL Cardiol Therapeutics Cardiovascular Rare 1 Phase 3 $124M 4
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 1 Phase 3 $187M 4
CLDX Celldex Therapeutics DermatologyImmunology+1 4 Phase 3 $2.20B 6
CGEN Compugen Oncology 4 Phase 3 $191M 7
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $858M 7
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 2 Approved — 6
DFTX Definium Therapeutics Neurology 2 Phase 3 $4.02B 4
IRON Disc Medicine GI/HepatologyHematology+2 Rare 2 Phase 3 $3.49B 9
DYN Dyne Therapeutics MetabolicNeurology Rare 1 NDA Submitted $3.00B 10
EXEL Exelixis CardiovascularOncology 3 Approved $16.7B 23
EYPT EyePoint Ophthalmology 1 Phase 3 $34.1M 2
FBIO Fortress Biotech DermatologyHematology+4 Rare 2 Approved $61.4M 16
GUTS Fractyl Health Metabolic 1 Phase 3 $12.8M 1
GNLX Genelux Oncology 1 Phase 3 $96.1M 3
GERN Geron Oncology 1 Approved $644M 3
GOSS Gossamer Bio Cardiovascular Rare 1 NDA Submitted $67.5M 4
GLSI Greenwich LifeSciences Oncology 1 Phase 3 $274M 1
HRMY Harmony Biosciences MetabolicNeurology Rare 4 Approved $1.94B 17
HROW Harrow Ophthalmology Rare 2 Approved $1.11B 15
HELP Helus Pharma Neurology 1 Phase 3 $575M 3
IDYA IDEAYA Biosciences Oncology 1 NDA Submitted $2.65B 15
IMTX Immatics Oncology 1 Phase 3 $958M 8
IMRX Immuneering Oncology 1 Phase 3 $224M 5
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 $116M 4
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
IMCR Immunocore DermatologyInfectious Disease+2 2 Approved $1.44B 12
IMVT Immunovant ImmunologyNeurology Rare 1 Phase 3 $6.87B 4
INMB Inmune Bio Dermatology Rare 1 Phase 3 $29.7M 1
INSM Insmed CardiovascularImmunology+3 Rare 2 Approved $26.7B 15
NTLA Intellia Therapeutics CardiovascularImmunology Rare 2 NDA Submitted $1.37B 3
IVVD Invivyd Infectious Disease 1 Approved $152M 5
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 12 Approved $4.49B 29
KROS Keros Therapeutics NeurologyOncology Rare 2 Phase 3 $222M 5
KPRX Kiora Pharmaceuticals Ophthalmology Rare 1 Phase 3 $4.1M 4
KOD Kodiak Sciences Ophthalmology 6 Phase 3 $6.33B 8
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $297M 6
LBRX LB Pharmaceuticals Neurology 1 Phase 3 $1.30B 3
LQDA Liquidia CardiovascularImmunology+1 Rare 2 Approved $5.11B 9
MAIA MAIA Biotechnology Oncology 1 Phase 3 $77.2M 8
MBX MBX Biosciences Metabolic Rare 1 Phase 3 $2.64B 4
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 1 Phase 3 $827M 16
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 2 Approved $1.54B 5
MIST Milestone Pharmaceuticals Cardiovascular 1 Approved $51.4M 2
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare 1 NDA Submitted $957M 4
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 $1.23B 11
NGEN NervGen Pharma Neurology 1 Phase 3 $211M 3
NGNE Neurogene Neurology Rare 1 Phase 3 $478M 1
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 2 NDA Submitted $2.33B 6
NRIX Nurix Therapeutics ImmunologyNeurology+1 2 Phase 3 $1.56B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 2 Phase 3 $660M 9
OCGN Ocugen Infectious DiseaseOphthalmology Rare 4 Phase 3 $257M 12
OCS Oculis Holding NeurologyOphthalmology Rare 1 Phase 3 $418M 5
OLMA Olema Pharmaceuticals Oncology 1 Phase 3 $633M 3
IRD Opus Genetics Ophthalmology Rare 2 Approved $391M 12
ORIC Oric Pharmaceuticals Oncology 1 Phase 3 $831M 5
OTLK Outlook Therapeutics Ophthalmology 2 Approved $87.9M 3
PTN Palatin Technologies ImmunologyMetabolic+1 1 Phase 3 $9.5M 5
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 2 Approved $8.14B 12
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $143M 3
RAPP Rapport Therapeutics Neurology 1 Phase 3 $1.41B 6
RLAY Relay Therapeutics DermatologyOncology Rare 1 Approved $3.64B 4
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare 1 Phase 3 $4.7M 11
RVMD Revolution Medicines Oncology 4 Approved $35.2B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare 5 Approved $8.08B 14
SGMT Sagimet Biosciences DermatologyMetabolic 1 Phase 3 $709M 3
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 1 Approved $1.58B 11
SLS SELLAS Life Sciences Group Oncology 1 Phase 3 $3.90B 9
SLDB Solid Biosciences CardiovascularNeurology Rare 1 Phase 3 $695M 6
STOK Stoke Therapeutics Neurology Rare 1 Phase 3 $1.73B 2
GPCR Structure Therapeutics MetabolicRespiratory Rare 2 Phase 3 $3.90B 5
SMMT Summit Therapeutics Oncology 3 NDA Submitted $8.53B 6
TSHA Taysha Gene Therapies Neurology Rare 1 Phase 3 $1.30B 4
TLX Telix Pharmaceuticals Oncology 4 Approved $3.01B 25
TENX Tenax Therapeutics Cardiovascular Rare 1 Phase 3 $64.7M 2
TGTX Tg Therapeutics Neurology Rare 1 Approved $9.48B 6
TVTX Travere Therapeutics MetabolicRenal Rare 1 Approved $4.91B 7
HURA TuHURA Biosciences Oncology 1 Phase 3 $92.1M 4
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 2 Approved $1.70B 10
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 8 Approved $230M 27
PCVX Vaxcyte Infectious Disease 2 Phase 3 $9.40B 7
VRCA Verrica Pharmaceuticals DermatologyOncology Rare 1 Approved $53.9M 4
VKTX Viking Therapeutics MetabolicNeurology Rare 2 Phase 3 $3.43B 9
VIR Vir Biotechnology Infectious DiseaseOncology Rare 1 Phase 3 $1.58B 6
VRDN Viridian Therapeutics ImmunologyOphthalmology 1 Approved $3.41B 7
VOR Vor Biopharma ImmunologyNeurology Rare 2 Phase 3 $1.12B 2
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 1 Phase 3 $69.4M 9
XFOR X4 Pharmaceuticals — 1 Approved $316M 2
XNCR Xencor ImmunologyNeurology+1 Rare 1 Approved $2.59B 28
XENE Xenon Pharmaceuticals Neurology Rare 3 NDA Submitted $3.81B 9
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 2 NDA Submitted $1.88B 11
ZNTL Zentalis Pharmaceuticals Oncology 1 Phase 3 $146M 1
ZYME Zymeworks OncologyRespiratory 1 Approved $1.78B 12